Company Analysis ASLAN Pharmaceuticals Limited
1. Summary
Advantages
- Price (0.635 $) is less than fair price (0.89 $)
- The stock's return over the last year (20.29%) is higher than the sector average (-31.05%).
- The company's current efficiency (ROE=332.81%) is higher than the sector average (ROE=9.61%)
Disadvantages
- Dividends (0%) are below the sector average (0.5473%).
- Current debt level 108.93% has increased over 5 years from 78.74%.
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| ASLAN Pharmaceuticals Limited | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | -22.6% | 2.3% |
| 90 days | 0% | -35.5% | 6.3% |
| 1 year | 20.3% | -31% | 31.5% |
ASLN vs Sector: ASLAN Pharmaceuticals Limited has outperformed the "Healthcare" sector by 51.34% over the past year.
ASLN vs Market: ASLAN Pharmaceuticals Limited has significantly underperformed the market by -11.22% over the past year.
Stable price: ASLN is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: ASLN with weekly volatility of 0.3902% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (0.635 $) is lower than the fair price (0.89 $).
Price significantly below the fair price: The current price (0.635 $) is 40.2% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.72).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (49.05).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (-3.98) is lower than that of the sector as a whole (4.82).
P/BV vs Market: The company's P/BV (-3.98) is lower than that of the market as a whole (3.18).
4.4. P/S
P/S vs Sector: The company's P/S indicator (4.41) is lower than that of the sector as a whole (33.75).
P/S vs Market: The company's P/S indicator (4.41) is lower than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-1.35) is higher than that of the sector as a whole (-22.17).
EV/Ebitda vs Market: The company's EV/Ebitda (-1.35) is lower than that of the market as a whole (28.35).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 1366.19% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (1366.19%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (123.79%).
5.4. ROE
ROE vs Sector: The company's ROE (332.81%) is higher than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (332.81%) is higher than that of the market as a whole (10.67%).
5.5. ROA
ROA vs Sector: The company's ROA (-179.56%) is lower than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (-179.56%) is lower than that of the market as a whole (6.44%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5473%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
